Worldwide Burden of Gynecological Cancer

  • R. Sankaranarayanan
  • J. Ferlay


 Cancer incidence, mortality, and  prevalence are commonly used indicators of cancer burden. Estimation of cancer burden is valuable for the formulation of cancer control policies and planning health services. The sources and methods of estimation of global data and the worldwide burden of gynecological cancers (malignant neoplasm of uterine cervix, corpus, ovary, vagina, vulva, and placenta) are described. Cervical cancer accounted for 487,300 new cases and 269,500 deaths; uterine corpus cancer for 233,300 new cases and 61,400 deaths; ovarian cancer for 230,000 new cases and 140,100 deaths; cancers of the vagina, vulva, placenta, and ill-defined sites together constituted 74,900 cases. Less developed countries accounted for more than 80% of the cervical cancer cases while almost 60% of uterine corpus cases occurred in the developed world. Earnest implementation of current developments in screening and vaccination has the potential to dramatically reduce the burden of cervical cancer. The differences in the outcome of cancer treatment across the world are due to vast disparities in health service infrastructures, human resources, service delivery, and accessibility to services. A significant proportion of patients are unable to access and avail or complete preventive, diagnostic, and therapy services in many countries due to inadequate health care services and financing. Formulation and translation of appropriate cancer control policies and investments in awareness creation, human resources development, and healthcare infrastructure are vital to reduce the current burden of gynecological cancer in low- and medium-resource countries. On the other hand, attention should be focused on emerging cost-effective options to sustain and further improve current control prospects in the developed world.


Ovarian Cancer Cervical Cancer Cervical Intraepithelial Neoplasia Gynecological Cancer Vulva Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

List of Abbreviations:


Alliance for Cervical Cancer Prevention


age-standardized rate


cervical intraepithelial neoplasia


human papillomavirus


International Agency for Research on Cancer


international statistical classification of diseases, 10th edition


National Cancer Control Programme


Surveillance, Epidemiology and End Results Programme


transvaginal sonography


visual inspection with acetic acid


World Health Organization


  1. Agosti JM, Goldie SJ. (2007). N Engl J Med. 356: 1908–1910.PubMedCrossRefGoogle Scholar
  2. Alliance for Cervical Cancer Prevention (ACCP). (2004). Planning and Implementing Cervical Cancer Prevention and Control Programs: A Manual for Managers. ACCP, Seattle.Google Scholar
  3. Altieri A, Franceschi S, Ferlay J, Smith J, La VC. (2003). Lancet Oncol. 4: 670–678.PubMedCrossRefGoogle Scholar
  4. Arbyn M, Autier P, Ferlay J. (2007). Ann Oncol. 18: 1423–1425.PubMedCrossRefGoogle Scholar
  5. Armstrong BK. (1992). Cancer Causes Control. 3: 569–579.PubMedCrossRefGoogle Scholar
  6. Badgwell D, Bast RC Jr. (2007). Dis Markers. 23: 397–410.PubMedGoogle Scholar
  7. Bosch FX, de Sanjose S. (2003). J Natl Cancer Inst Monogr. 31: 3–13.PubMedGoogle Scholar
  8. Bray F, Dos Santos Silva I, Moller H, Weiderpass E. (2005). Cancer Epidemiol Biomarkers Prev. 14: 1132–1142.PubMedCrossRefGoogle Scholar
  9. Castellsague X, Bosch FX, Munoz N, Meijer CJ, Shah KV, de Sanjose S, Eluf-Neto J, Ngelangel CA, Chichareon S, Smith JS, Herrero R, Moreno V, Franceschi S. (2002). N Engl J Med. 346: 1105–1112.PubMedCrossRefGoogle Scholar
  10. Chia KS, Du WB, Sankaranarayanan R, Sankila R, Seow A, Lee HP. (2001). Int J Cancer. 93: 142–147.PubMedCrossRefGoogle Scholar
  11. Curado MP, Edwards B, Shin HR, Strom H, Ferlay J, Heanue M, Boyle P. (2007). Cancer Incidence in Five Continents, vol. 9. IARC Scientific Publications No. 160, IARC, Lyon.Google Scholar
  12. Denny L, Kuhn L, De Sousa M, Pollack AE, Dupree W, Wright TC Jr. (2005). JAMA. 294: 2173–2181.PubMedCrossRefGoogle Scholar
  13. Ferlay J, Bray F, Pisani P, Parkin DM. (2004). GLOBOCAN 2002. Cancer Incidence, Mortality and Prevalence Worldwide. IARC Cancer Base No. 5 version 2.0. IARC, Lyon.Google Scholar
  14. Franco EL. (2003). J Natl Cancer Inst Monogr. 31: 89–96.PubMedGoogle Scholar
  15. Franco EL, Ferenczy A. (2007). Future Oncol. 3: 319–327.PubMedCrossRefGoogle Scholar
  16. Gondos A, Brenner H, Wabinga H, Parkin DM. (2005). Br J Cancer. 92: 1808–1812.PubMedCrossRefGoogle Scholar
  17. Gondos A, Chokunonga E, Brenner H, Parkin DM, Sankila R, Borok MZ, Chirenje ZM, Nyakabau AM, Bassett MT. (2004). Int J Cancer. 112: 860–864.PubMedCrossRefGoogle Scholar
  18. Gustafsson L, Ponten J, Bergstrom R, Adami HO. (1997). Int J Cancer. 71: 159–165.PubMedCrossRefGoogle Scholar
  19. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, Jenkins D, Schuind A, Costa Clemens SA, Dubin G. (2006). Lancet. 367: 1247–1255.PubMedCrossRefGoogle Scholar
  20. Herzog TJ, Monk BJ. (2007). Am J Obstet Gynecol. 197: 566–571.PubMedCrossRefGoogle Scholar
  21. IARC. (2004). IARC Handbooks on Cancer Prevention, vol. 10: Cervix Cancer Screening. IARC, Lyon.Google Scholar
  22. IARC. (2007). IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. vol. 90: Human Papillomaviruises. IARC, Lyon.Google Scholar
  23. Judson PL, Habermann EB, Baxter NN, Durham SB, Virnig BA. (2006). Obstet Gynecol. 107: 1018–1022.PubMedCrossRefGoogle Scholar
  24. Koliopoulos G, Arbyn M, Martin-Hirsch P, Kyrgiou M, Prendiville W, Paraskevaidis E. (2007). Gynecol Oncol. 104: 232–246.PubMedCrossRefGoogle Scholar
  25. Koutsky LA, Harper DM. (2006). Vaccine. 24: S114–S121.CrossRefGoogle Scholar
  26. Loukovaara M, Pukkala E, Lehtovirta P, Leminen A. (2004). Gynecol Oncol. 92: 252–255.PubMedCrossRefGoogle Scholar
  27. Luo W, Morrison H, de Groh M, Waters C, DesMeules M, Jones-McLean E, Ugnat AM, Desjardins S, Lim M, Mao Y. (2007). Chronic Dis Can. 27: 135–144.PubMedGoogle Scholar
  28. Marugame T, Hirabayashi Y. (2007). Jpn J Clin Oncol. 37: 802–803.PubMedCrossRefGoogle Scholar
  29. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ. (2003). N Engl J Med. 348: 518–527.PubMedCrossRefGoogle Scholar
  30. Nandakumar A, Gupta PC, Gangadharan P, Visweswara RN, Parkin DM. (2005). Int J Cancer. 116: 740–754.PubMedCrossRefGoogle Scholar
  31. Parkin DM, Bray F, Ferlay J, Pisani P. (2005). CA Cancer J Clin. 55: 74–108.PubMedCrossRefGoogle Scholar
  32. Parkin DM, Bray FI, Devesa SS. (2001). Eur J Cancer. 37: S4–S66.PubMedCrossRefGoogle Scholar
  33. Pisani P, Bray F, Parkin DM. (2002). Int J Cancer. 97: 72–81.PubMedCrossRefGoogle Scholar
  34. Ries LAG, Young JL, Keel GE, Eisner MP, Lin YD, Horner MJ. (2007). SEER Survival Monograph: Cancer Survival Among Adults: U.S. SEER Program, 1988–2001, Patient and Tumor Characteristics. NIH Pub. No. 07–6215. NIH, Bethesda.Google Scholar
  35. Sankaranarayanan R, Esmy PO, Rajkumar R, Muwonge R, Swaminathan R, Shanthakumari S, Fayette JM, Cherian J. (2007). Lancet. 370: 398–406.PubMedCrossRefGoogle Scholar
  36. Sankaranarayanan R, Nene BM, Dinshaw KA, Mahe C, Jayant K, Shastri SS, Malvi SG, Chinoy R, Kelkar R, Budukh AM, Keskar V, Rajeshwarker R, Muwonge R, Kane S, Parkin DM, Chauhan MK, Desai S, Fontaniere B, Frappart L, Kothari A, Lucas E, Panse N. (2005). Int J Cancer. 116: 617–623.PubMedCrossRefGoogle Scholar
  37. Sankaranarayanan R, Budukh AM, Rajkumar R. (2001). Bull World Health Organ. 79: 954–962.PubMedGoogle Scholar
  38. Sankaranarayanan R, Black RJ, Parkin DM. (1998). Cancer Survival in Developing Countries. IARC Scientific Publications No 15. IARC, Lyon.Google Scholar
  39. Sankaranarayanan R, Swaminathan R, Black RJ. (1996). Cancer. 78: 2461–2464.PubMedCrossRefGoogle Scholar
  40. Smith HO, Qualls CR, Prairie BA, Padilla LA, Rayburn WF, Key CR. (2003). Obstet Gynecol. 102: 978–987.PubMedCrossRefGoogle Scholar
  41. Smith HO, Tiffany MF, Qualls CR, Key CR. (2000). Gynecol Oncol. 78: 97–105.PubMedCrossRefGoogle Scholar
  42. Somoye G, Olaitan A, Mocroft A, Jacobs I. (2005). J Obstet Gynaecol. 25: 35–38.PubMedCrossRefGoogle Scholar
  43. The EUROCARE Working Group. (2003). Ann Oncol. 14: v61–118.Google Scholar
  44. The Future II Study. (2007). N Engl J Med. 356: 1915–1927.Google Scholar
  45. United Nations. (2006). Population Division ( World Population Prospects (The 2006 revision).
  46. Vizcaino AP, Moreno V, Bosch FX, Munoz N, Barros-Dios XM, Parkin DM. (1998). Int J Cancer. 75: 536–545.PubMedCrossRefGoogle Scholar
  47. World Health Organization. (2002). National Cancer Control Programmes: Policies and Managerial Guidelines, 2nd ed. WHO, Geneva.Google Scholar

Copyright information

© Springer Science+Business Media LLC 2010

Authors and Affiliations

  • R. Sankaranarayanan
    • 1
  • J. Ferlay
    • 2
  1. 1.Head, Screening GroupInternational Agency for Research on CancerLyonFrance
  2. 2.Descriptive Epidemiology, Data Analysis and Interpretation GroupInternational Agency for Research on CancerLyonFrance

Personalised recommendations